Yarrow Bioscience, Inc.

Yarrow Bioscience, Inc.

NNASDAQ:YARW
13.93
USD
-4.10
(-22.74%)
-188.57EPS
91.20MMarket Cap
Mar 04Next Earn
Yarrow Bioscience, Inc.
NASDAQ:YARW
(Nasdaq Stock Market)

Recent

price

13.93

P/E

ratio

- -

div

yld

- -

ROIC.AI

2025
TTM
USD
- -
0.38
Revenue per Share
- -
-188.83
Basic EPS, GAAP
- -
- -
Free Cash Flow per Basic Share
- -
- -
Dividend per Share
-25.33
7.87
Book Value per Share
-25.33
7.87
Tangible Book Value per Share
1
- -
Basic Weighted Avg Shares
- -
- -
Sales/Revenue/Turnover
- -
-8,734.94
Operating Margin (%)
- -
- -
Depreciation Expense
- -
-83
Net Income, GAAP
- -
- -
Effective Tax Rate (%)
- -
-49,699.4
Profit Margin (%)
28
22
Working Capital
- -
- -
LT Debt
29
22
Total Equity
- -
- -
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Jun'26
ST Debt
- -
LT Borrowings
- -
LT Finance Leases
- -
Preferred Equity and Hybrid Capital
- -
Shares Outstanding
3
Market Capitalization
91

Working Capital

USD

•

in mil. unless spec.
Jun'26
Total Current Assets
24
Cash, Cash Equivalents & STI
23
Accounts Receivable, Net
- -
Inventories
- -
Total Current Liabilities
2
Payables & Accruals
1
ST Debt
- -
Deferred Revenue
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-336.55
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
-3.21
-3.5
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Yarrow Bioscience, Inc. operates as a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology and related diseases. The company pursues a portfolio of drug candidates and platform technologies designed to advance cancer treatment, with an emphasis on targeted, patient-centric approaches and companion diagnostic strategies. Main products and services - Therapeutic candidates: development of targeted oncology therapies through small molecules, biologics, and antibody-drug conjugates designed to improve efficacy and safety profiles in specific cancer indications; advancement of combination regimens with existing treatments where applicable - Platform technologies: research and development platforms that enable precision medicine, including biomarker-driven patient selection, companion diagnostic integration, and streamlined translational science to support clinical development - Clinical development services: nonclinical and preclinical collaboration for candidate evaluation, translational research, pharmacology/toxicity assessment, and early-stage clinical trial design - Regulatory and filing support: preparation and submission of regulatory documentation, engagement with health authorities, and strategy for accelerated or conditional approvals where feasible - Manufacturing and supply chain planning: early-stage process development support, scale-up planning, and potential manufacturing partnerships to support clinical and later-stage production - Commercialization planning services: market access analyses, competitive positioning, pricing and reimbursement strategy considerations, and lifecycle management insights for future product launches Latest major company changes - Strategic partnerships: enters collaborations with pharmaceutical and biotechnology entities to co-develop or license oncology programs, including optional or milestone-based agreements intended to broaden the pipeline and accelerate clinical development - Funding and capitalization: secures financing rounds and strategic investments to support ongoing research programs, clinical trials, and platform expansion - Product and platform advancements: advances pipeline through initiation of new clinical trials, expansion of platform capabilities, and integration of biomarker-driven approaches into trial design - Corporate actions: organizational refinements or restructurings as the company scales its R&D and operations to support an expanded clinical portfolio - Geographic and operational expansion: broadens operational footprint to support multicenter clinical trials and potential regional manufacturing or partner arrangements Additional context - Industry and segments: biopharmaceuticals focused on oncology, precision medicine, and biomarker-driven therapies - Target markets: global cancer care providers, academic medical centers, contract research and manufacturing organizations, and payer landscapes in major markets - Geographic operations: headquartered in the United States with research and development activities potentially spanning multiple sites; geographic reach extends to collaboration partners and trial sites internationally - Founding year and headquarters: established in the early 2020s; headquarters located in the United States - Subsidiaries/parent relationships: operates as an independent publicly traded company with potential subsidiary arrangements tied to regional operations or development programs - Other notable considerations: maintains a focus on translating laboratory discoveries into clinically meaningful oncology therapies, with an emphasis on biomarker-informed patient selection and precision medicine approaches

Company News

  • Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update

  • Buy, Sell, or Hold? Friday’s Top Upgrades and Downgrades: Becton Dickinson, BJ’s Wholesale Club, Cogent Communications, Fervo Energy, JinkoSolar, Molson-Coors, Pfizer, SiTime, Steven Madden, and More

  • Yarrow Bioscience Announces Participation in November Investor Events

  • Contrasting Yarrow Bioscience (NASDAQ:YARW) and Atara Biotherapeutics (NASDAQ:ATRA)

  • Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

  • Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

  • Yarrow Bioscience Announces Proposed Underwritten Public Offering

  • Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease

  • VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

  • VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

  • VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

  • Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 35.7%

  • Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)

  • VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 61.3% in February

  • Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

  • $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)

  • VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript

  • VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders

  • VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement